Navigation Links
Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
Date:11/2/2010

llment, site qualification and start-up activities continued for the PEARL-SC Phase 2b study, which is examining the therapeutic benefit of A-623 in patients with systemic lupus erythematosus (lupus).  Enrollment has begun in the United States and, subsequent to the third quarter, sites in Colombia and Mexico were initiated and are enrolling patients. The study remains on track for a biomarker analysis in the first half of 2011.  The primary endpoint of the PEARL-SC study will be an SLE responder index.  Details regarding the study can be found at http://www.clinicaltrials.gov/ct2/show/NCT01162681.
  • VISTA-16 site activations and patient enrollment are on schedule as of the end of the third quarter. Regulatory approvals and site initiations are ongoing in additional geographies. Stephen Nicholls, MD, John Kastelein, MD, and Greg Schwartz, MD, along with the Cleveland Clinic Coordinating Center for Clinical Research (C5), are providing executive oversight of the study.
  • Site monitoring and audits continue for the VISTA-16 study which is designed to reduce inflammation in high-risk patients following an ACS. Details regarding the study can be found at http://www.clinicaltrials.gov/ct2/show/NCT01130246.
  • The Journal of the American College of Cardiology (JACC) published an article in September 2010 based upon the FRANCIS study, which is investigating the effects of varespladib methyl on cardiovascular biomarkers in ACS patients.
  • IMPACTS Phase 2 final study report is expected before the end of the year. Options for the next stage of development are under review and protocol is currently being finalized.

  • Manufacturing

  • The second manufacturing campaign of A-623 clinical material was completed and passed all quality assurance specifications.
  • The Company continues to make
    '/>"/>

  • SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
    2. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
    3. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
    4. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    5. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
    6. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    7. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
    8. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
    9. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    10. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
    11. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... , Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... mechanical circulatory support therapies to save, support and restore ... the 2014 Morgan Stanley Global Healthcare Conference on Wednesday, ... President and Chief Executive Officer, will provide an update ... Time (9:55 a.m., Pacific Daylight Time).   ...
    (Date:8/29/2014)... Research and Markets has announced the addition ... report to their offering. Benefiting ... for medical expenses, the Chinese orthopedic instrument market demand ... CAGR of 19.2% during 2009-2013. Trauma products, spine products ... instruments in China , of which ...
    (Date:8/29/2014)... -- Research and Markets  has announced the addition of ... report to their offering. The Central Nervous ... largest segments of pharmaceuticals industry. The numbers of CNS disorders ... were unable to meet the market requirements. There has been ... especially over the past two decades. The market for CNS ...
    Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2
    ... Nov. 18 Disabled American Veterans (DAV) announces the launch of ... 75% and when the card is used, 50 cents will be ... , The free prescription drug cards may be used by ... a time when non-profit organizations are seeing a decline in charitable ...
    ... , CLEVELAND, Nov. 18 ... consumers over the counter throughout Greater Cleveland, one of two cities ... a nationwide product launch. The MyClyns spray has been used and ... years and is now available on store shelves for the very ...
    Cached Medicine Technology:FREE Drug Discount Card Saves Money on Prescriptions and Raises Funds for America's Disabled Veterans 2MyClyns(R) Now Available to Greater Clevelanders 2
    (Date:9/1/2014)... be able to convince your brain that healthy foods taste ... included eight overweight and obese people who were enrolled in ... react to different foods. These participants were compared to a ... in the program. Both groups had MRI brain scans ... later. The scans revealed that the people in the weight-loss ...
    (Date:9/1/2014)... 2014 An operating theatre or operating ... performing surgical operations. An operating room comprises a myriad ... operating room lights, imaging displays as well as integration ... Transparency Market Research, a U.S.-based market research firm, the ... 4.5 billion by 2019. , According to this ...
    (Date:9/1/2014)... Dennis Thompson HealthDay Reporter ... Ebola drug previously given to two American aid workers successfully ... in laboratory tests, researchers report. The drug, ZMapp, prompted ... they didn,t get the medication until five days after infection. ... who were days or even hours away from death, said ...
    (Date:9/1/2014)... The National Association of Hispanic Nurses ... Bazarko, DNP, MPH, RN, and Adriana Perez, PhD, Rn, ... of Nursing. They will be inducted with Immediate Past ... induction we reported last May. , Our three members ... 2014 American Academy of Nursing Policy Conference in Washington, ...
    (Date:9/1/2014)... involved in federally-filed Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ) are ... where issues related to claims involving the pain reliever ... Bernstein Liebhard LLP reports. , According to a ... the meeting is scheduled to take place on September ... of several Tylenol conferences that have taken place this ...
    Breaking Medicine News(10 mins):Health News:Train Your Brain to Choose Fruit Salad Over French Fries 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4
    ... St. Luke,s Closure to Have Disproportionate Impact On Latinos, Other ... ... Sutter Health,s planned,closure of St. Luke,s Hospital in San Francisco ... as evidenced by new state,data released today by the California ...
    ... more than doubled the odds, study found , , THURSDAY, Oct. ... conditions more than double their risk of needing subsequent surgery ... was true regardless of what type of surgical technique was ... article is published in the Oct. 27 issue of ...
    ... lowers blood pressure might help prevent Alzheimer disease ... the most common form of dementia, is characterized by ... beta-amyloid protein. Recent evidence indicates that some drugs used ... the risk of developing AD. In a new study, ...
    ... PHILADELPHIA A new Center for Excellence in Ethical, ... at the University of Pennsylvania School of Medicine, a ... Sciences, the Wharton School and the Annenberg School for ... of Genetic Healthcare Technology (Penn CIGHT) will receive over ...
    ... of Michigan is the lead research institution in a ... the health consequences on victims in disasters. , ... Health Research, includes researchers from U-M, Dartmouth Medical School, ... University of Oklahoma. The center is funded by the ...
    ... prevents formation of beta-amyloid clumps in mice, study says ... pressure drug valsartan shows the ability to reduce Alzheimer,s ... value of valsartan, marketed as Diovan, emerged from a ... drugs, said study author Dr. Giulio Maria Pasinetti, a ...
    Cached Medicine News:Health News:CNA Presents New Data on Sutter's Medical Redlining 2Health News:CNA Presents New Data on Sutter's Medical Redlining 3Health News:Hysterectomy May Boost Incontinence Risk 2Health News:Hysterectomy May Boost Incontinence Risk 3Health News:JCI table of contents: Oct. 25, 2007 2Health News:JCI table of contents: Oct. 25, 2007 3Health News:JCI table of contents: Oct. 25, 2007 4Health News:JCI table of contents: Oct. 25, 2007 5Health News:JCI table of contents: Oct. 25, 2007 6Health News:JCI table of contents: Oct. 25, 2007 7Health News:JCI table of contents: Oct. 25, 2007 8Health News:JCI table of contents: Oct. 25, 2007 9Health News:Penn wins $5M to start center for ethical, legal and social implications research 2Health News:Penn wins $5M to start center for ethical, legal and social implications research 3Health News:U-M to lead disaster aftermath research center 2Health News:Blood Pressure Drug Might Work Against Alzheimer's 2
    ... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
    ... Durable ergonomic chairs with concave seats ... Select options like seats, backrests, armrests, and ... Series for top performance in a variety ... room, static control, health care and office. ...
    ... seats and large backrests with lumbar support ... and casters and glides. • Choose the ... variety of environments including: industry, education, laboratory, ... office. • With tubular base • unit ...
    ... seats and large backrests with lumbar support ... and casters and glides. • Choose the ... variety of environments including: industry, education, laboratory, ... office. • With tubular base • unit ...
    Medicine Products: